Computational drug repurposing against histone acetyltransferase p300 for non-hormonal treatment of endometriosis using virtual screening and molecular dynamics simulations
This study used virtual screening and molecular dynamics simulations to identify Bictegravir as a promising p300 inhibitor for non-hormonal endometriosis treatment, demonstrating its favorable binding stability compared to other FDA-approved drugs.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This study utilized computational drug repurposing to identify potential non-hormonal treatments for endometriosis by targeting the histone acetyltransferase p300, which drives inflammation and invasion. The researchers conducted a virtual screening of 2,083 FDA-approved drugs against the p300 ligand-binding domain, followed by molecular dynamics simulations and MM-PBSA analysis to evaluate binding stability. Three compounds, including Naldemedine, Bictegravir, and Zavegepant, showed favorable docking affinities, with Bictegravir demonstrating the most stable interaction in subsequent simulations. This paper is centrally about endometriosis — specifically exploring a novel epigenetic target for non-hormonal therapeutic intervention through in silico methods.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
3,207 characters
· extracted from
oa-html
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
References (80)
- Assessing research gaps and unmet needs in endometriosis via openalex
- Cancer-Associated Mutations in Endometriosis without Cancer via openalex
- Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium via openalex
- Diagnosis and management of endometriosis via openalex
- Endometriosis via openalex
- GnRH agonists in the treatment of symptomatic endometriosis: a review via openalex
- Gonadotrophin-releasing hormone analogues for pain associated with endometriosis via openalex
- Iatrogenic endometriosis harbors somatic cancer-driver mutations via openalex
- Loss of ARID1A/BAF250a expression in ovarian endometriosis and clear cell carcinoma via openalex
- Management of endometriosis-related infertility: Considerations and treatment options via openalex
- (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes via openalex
- Pathogenesis of Endometriosis: New Insights into Prospective Therapies via openalex
- Preoperative and perioperative intervention reduces the risk of recurrence of endometriosis in mice caused by either incomplete excision or spillage and dissemination via openalex
- The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis via openalex
- The Origin and Pathogenesis of Endometriosis via openalex
- W2206954826 via openalex
- W2257896588 via openalex
- W2345322579 via openalex
- W2528045957 via openalex
- W2540545429 via openalex
- W2547857376 via openalex
- W2555870966 via openalex
- W2895791749 via openalex
- W3018207421 via openalex
- W3026107616 via openalex
- W3040680043 via openalex
- W3048717461 via openalex
- W3101617773 via openalex
- W3161035049 via openalex
- W3165294846 via openalex
- W3172596470 via openalex
- W3202287440 via openalex
- W4211238337 via openalex
- W4282975873 via openalex
- W4283643775 via openalex
- W4296830446 via openalex
- W4311442002 via openalex
- W4313236531 via openalex
- W4313260078 via openalex
- W4318766616 via openalex
- W4321597873 via openalex
- W4321610320 via openalex
- W4386348917 via openalex
- W4388915232 via openalex
- W4391168739 via openalex
- W4391358563 via openalex
- W4391406450 via openalex
- W4400499601 via openalex
- W4402066138 via openalex
- W4402130540 via openalex
- W4402401191 via openalex
- W4402491218 via openalex
- W4402827768 via openalex
- W4403822177 via openalex
- W4404143454 via openalex
- W4407167810 via openalex
- W4407227630 via openalex
- W4409065268 via openalex
- W4412159600 via openalex
- W4412707770 via openalex
- W4414209297 via openalex
- W4415667260 via openalex
- W7118092552 via openalex
- W7128452746 via openalex
- W7134973459 via openalex
- W7151629857 via openalex
- W1031578623 via openalex
- W1884928119 via openalex
- W1968984443 via openalex
- W2021520922 via openalex
- W2024180698 via openalex
- W2025995838 via openalex
- W2027489327 via openalex
- W2029667189 via openalex
- W2035687084 via openalex
- W2039823376 via openalex
- W2057477511 via openalex
- W2081693079 via openalex
- W2125236946 via openalex
- W2131128934 via openalex
Source provenance
- openalex
- last seen: 2026-11-19T06:04:33.792782+00:00